Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.
Henk M Lokhorst
Consultant or Advisory Role - Genmab
Honoraria - Celgene; Janssen-Cilag
Research Funding - Genmab
Torben Plesner
Consultant or Advisory Role - Genmab
Honoraria - Genmab
Research Funding - Janssen Pharmaceutical
Expert Testimony - Genmab
Peter Gimsing
No relevant relationships to disclose
Hareth Nahi
No relevant relationships to disclose
Monique Minnema
Honoraria - Janssen-Cilag
Ulrik Niels Lassen
No relevant relationships to disclose
Jakub Krejcik
No relevant relationships to disclose
Jacob Laubach
No relevant relationships to disclose
Steen Lisby
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Linda Basse
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Paul Gerard Guy Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis